TB-500 (Thymosin Beta-4) Research 2026 — Molecular Profile, Actin-Sequestering Mechanism & Verification

TB-500 is the name the research-compound market has attached to thymosin beta-4 (Tβ4), one of the most-studied actin-regulating peptides in cell biology. Thymosin beta-4 is a 43-residue, naturally occurring peptide that functions as the principal G-actin-sequestering molecule in most mammalian cells, and it has been examined across three decades of preclinical work in wound-repair, corneal, cardiac, and neural models. For laboratories modeling cytoskeletal dynamics, cell migration, angiogenesis, and tissue-repair signaling, TB-500 has become a compound of sustained interest precisely because it connects a single, well-characterized molecular sequence to a defined and heavily replicated biochemical mechanism.

This guide is written for qualified laboratory researchers sourcing TB-500 / thymosin beta-4 as a research compound. It covers the molecular profile, the mechanism at the protein and pathway level as described in the published literature, representative preclinical and in-vitro research data, real citations you can verify yourself through PubMed, and how to evaluate the analytical documentation that should accompany a peptide of this size. It also notes the current U.S. regulatory context, because TB-500 is one of the peptides on the FDA Pharmacy Compounding Advisory Committee’s July 2026 review docket.

For in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use.

Section 1 — Molecular Profile

Thymosin beta-4 is a mid-length, highly acidic linear peptide with no cysteine residues and a single methionine, giving it a distinctive mass signature and a well-behaved reversed-phase chromatographic profile.

• Compound name: Thymosin beta-4 (Tβ4); marketed in the research market as TB-500
• CAS number: 77591-33-4
• Molecular formula: C₂₁₂H₃₅₀N₅₆O₇₈S
• Molecular weight: ≈ 4,963.4 g/mol
• Length: 43 amino acids
• N-terminus: N-terminally acetylated serine
• Sequence: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
• Actin-binding domain: the central 17-residue region built around the conserved KLKKTETQ motif
• Appearance: White lyophilized powder; reconstituted in aqueous buffer for in-vitro work

A point of terminology matters here for sourcing. In the primary scientific literature the molecule is almost always called thymosin beta-4 and studied as the full 43-residue peptide. In the research-compound market the label “TB-500” is used broadly — sometimes for the complete 43-residue Tβ4 sequence and sometimes for a shorter synthetic construct centered on the actin-binding domain. Because the two are not analytically identical, the single most important documentation question for this compound is which sequence is actually in the vial, a question only mass-spectrometric identity data can answer. A competent supplier states the sequence explicitly and backs it with an identity mass.

At roughly 4,963 g/mol, Tβ4 is substantially larger than the short bioregulator peptides, and its sequence is unusually rich in acidic (glutamate, aspartate) and basic (lysine) residues, giving it a high net charge and excellent aqueous solubility. The single methionine residue means methionine oxidation (+16 Da) is the characteristic degradation product to watch for on LC-MS, and the absence of cysteine means there is no disulfide chemistry to complicate the analysis — a well-resolved reversed-phase method plus a clean protonated-molecule envelope is the expected fingerprint.

Section 2 — Mechanism (Pathway Language)

Thymosin beta-4 is studied primarily as an actin-sequestering peptide and as an extracellular signaling molecule. The published mechanistic literature describes it at the level of protein binding, cytoskeletal dynamics, and intracellular signaling pathways — not at the level of any clinical endpoint.

G-actin sequestration and cytoskeletal dynamics. The defining biochemical function of Tβ4 is that it binds monomeric globular actin (G-actin) in a 1:1 complex and holds it in an unpolymerized, sequestered state. Because the equilibrium between G-actin and filamentous F-actin governs how quickly a cell can remodel its cytoskeleton, Tβ4 acts as an intracellular buffer of the polymerizable actin pool. In assays of cell migration and cytoskeletal remodeling, this actin-buffering activity is the mechanistic starting point from which the peptide’s other reported effects are interpreted.

Cell-migration and integrin-linked kinase signaling. Beyond passive actin binding, Tβ4 has been reported to promote directed cell migration. The most-cited mechanistic route runs through integrin-linked kinase (ILK): a 2004 study in Nature reported that thymosin beta-4 forms a functional complex with PINCH and ILK, activating the survival kinase Akt/PKB and promoting cardiac and endothelial cell migration and survival in culture. This positioned Tβ4 as more than a structural actin buffer — as a peptide that engages a defined cell-survival and motility signaling axis.

Angiogenesis and anti-inflammatory signaling. In endothelial-cell systems, Tβ4 is studied for its association with angiogenic behavior — endothelial migration, tube formation, and vessel-sprouting endpoints in vitro. A separate line of work in ocular-surface and epithelial systems characterizes Tβ4 as modulating inflammatory signaling, including reported effects on NF-κB-associated pathways and on markers of the inflammatory response in cultured cells.

In accordance with research-context framing, this article describes thymosin beta-4 strictly at the protein-binding, cytoskeletal, and signaling-pathway level. It is studied for its interaction with actin, ILK/Akt signaling, and endothelial and epithelial cell behavior in controlled systems; no human outcome, therapeutic, or physiological benefit is claimed or implied.

Section 3 — Preclinical & In-Vitro Research Data

The thymosin beta-4 literature is unusually deep for a peptide of this class, spanning cell culture, rodent injury models, and mechanistic molecular biology across several tissue systems.

In-vitro actin binding and cell migration. The foundational biochemistry established Tβ4 as the major intracellular G-actin-sequestering peptide and characterized its 1:1 binding to monomeric actin. Cell-culture work then reported that Tβ4 promotes keratinocyte, endothelial, and fibroblast migration — the cellular behaviors underlying tissue-repair models — providing a mechanistic link between actin regulation and directed cell movement.

Dermal wound-repair models. In classic preclinical work, thymosin beta-4 was applied in rodent dermal-wound and excisional models, with reported effects on the rate of wound closure, keratinocyte migration, and markers of angiogenesis in the wound bed. These are animal-model endpoints that characterize the compound’s behavior in controlled repair systems; they do not constitute evidence of any human outcome.

Corneal and ocular-surface research. A large body of work has examined Tβ4 in corneal epithelial and ocular-surface models, reporting effects on epithelial-cell migration, wound closure, and inflammatory-marker suppression in vitro and in preclinical models. This program advanced far enough that an ophthalmic Tβ4 formulation entered controlled clinical evaluation for corneal indications — work that used the full-length peptide under a distinct drug-development pathway and does not transfer to the research-compound market.

Cardiac injury models. Following the 2004 ILK/Akt mechanism report, thymosin beta-4 was studied in rodent myocardial-infarction models, with published work examining cardiomyocyte survival, cell migration, epicardial activation, and scar and fibrosis endpoints after coronary-artery ligation. Later mechanistic studies debated the extent of epicardial cell reprogramming, making the cardiac literature a useful example of how replication and reinterpretation refine a mechanistic claim over time.

Across these studies, the recurring experimental thread is a measurable molecular or cellular endpoint — actin-binding stoichiometry, cell-migration distance, capillary-density counts, or infarct and fibrosis measurements — quantified in a defined cell or animal system.

Section 4 — Published Literature (Verifiable Citations)

The following are real, published references retrievable through PubMed and PubMed Central (PMC). Researchers are encouraged to read the primary sources directly.

• Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. “Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair.” Nature. 2004;432(7016):466–472. PubMed: 15565145 — the foundational ILK/Akt cell-migration and cardiac-repair mechanism paper.
• Malinda KM, Sidhu GS, Mani H, et al. “Thymosin beta4 accelerates wound healing.” Journal of Investigative Dermatology. 1999;113(3):364–368 — early dermal wound-repair and keratinocyte-migration study.
• Sosne G, Qiu P, Kurpakus-Wheater M. “Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent.” Clinical Ophthalmology. 2010. PubMed: 19668473 — corneal epithelial migration and inflammatory-signaling review.
• Sosne G, Qiu P, Kurpakus-Wheater M, Steckis JA. “Thymosin beta4 and corneal wound healing: visions of the future.” PubMed: 20536468 — mechanistic and translational overview of the ocular-surface program.
• Wang Y, et al. “Thymosin β4 Protects against Cardiac Damage and Subsequent Cardiac Fibrosis in Mice with Myocardial Infarction.” Cardiovascular Therapeutics. 2022 — recent preclinical cardiac-injury and fibrosis study.
• “Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing.” PubMed: 41235866 — recent protein-engineering work fusing two Tβ4 actin-binding domains into a single construct.

Citing real primary literature is a core part of the PYXAX research-context standard. Any source — vendor or publication — that references “studies” without traceable identifiers should be treated with caution. Because thymosin beta-4 has both a deep basic-science literature and a separate pharmaceutical development history under the full-length sequence, the strongest evidentiary practice is to read the primary Nature and tissue-specific reports directly and to keep clear the distinction between full-length Tβ4 drug-development data and research-market “TB-500” material.

Section 5 — Research Applications (In-Vitro Use Cases)

Within qualified laboratory settings, thymosin beta-4 is used as a reference and probe compound in several categories of in-vitro and preclinical work:

• Actin-dynamics assays — as the canonical G-actin-sequestering reference peptide in studies of actin polymerization equilibrium and cytoskeletal remodeling.
• Cell-migration research — as a reference agonist in scratch-wound, transwell, and Boyden-chamber migration assays using keratinocytes, endothelial cells, and fibroblasts.
• Angiogenesis models — as a test agent in endothelial tube-formation and vessel-sprouting assays.
• Corneal / epithelial repair systems — as a comparator in ocular-surface and epithelial wound-closure models.
• Cardiac and cardioprotection research — as a probe in cardiomyocyte survival, ILK/Akt signaling, and preclinical infarct-model work.
• Analytical method development — as a defined 43-residue, single-methionine peptide standard for validating reversed-phase HPLC and LC-MS identity and oxidation-monitoring methods.

Each of these applications is an in-vitro or preclinical research use. Compounds supplied for research are not intended for, and must not be used in, any human or veterinary context.

Section 6 — How to Evaluate a Source

Thymosin beta-4 is a large peptide sold under an ambiguous market name, which makes analytical documentation more — not less — important. The following steps separate verifiable sourcing from marketing claims.

Step 1 — Confirm which sequence you are buying. Because “TB-500” is used for both the full 43-residue Tβ4 and shorter fragments, the COA and product page should state the exact sequence and molecular weight. If a listing does not specify, treat that as a documentation gap, not a detail.

Step 2 — Confirm the testing laboratory is named. “Third-party tested” is meaningless without a named, accredited laboratory. Look for an ISO 17025-accredited facility or equivalent recognized accreditation, and a COA that names the lab that tested the specific batch.

Step 3 — Confirm identity by mass spectrometry. A genuine full-length Tβ4 sample should present a protonated-molecule envelope consistent with a ~4,963 g/mol 43-residue peptide on LC-MS, with a multiply-charged ion series expected for a peptide carrying many charged residues. A COA that reports only “purity” without an identity mass is incomplete.

Step 4 — Confirm chromatographic purity and check for methionine oxidation. HPLC should show a single dominant peak. For a single-methionine peptide, a +16 Da oxidation product is the characteristic detectable impurity; a well-resolved method and an accompanying mass spectrum will reveal it.

Step 5 — Verify lot specificity and a complete panel. The batch number on the COA must match the vial label and correspond to the production lot — not a single historical testing event applied across an entire catalog. A COA you can verify independently, through a QR-linked laboratory portal or a searchable community database, is the standard to hold. For cell-based migration and signaling work, purity and identity should be accompanied by endotoxin and heavy-metal data, both of which can confound sensitive assay systems.

Section 7 — Regulatory Context (July 2026)

Researchers sourcing thymosin beta-4 in the United States should be aware of the current compounding-review landscape. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to review a set of peptides — including TB-500 / thymosin beta-4 — for potential inclusion on the Section 503A Bulk Drug Substances List. Separately, in April 2026 the Department of Health and Human Services confirmed the removal of a group of peptides from the compounding “Category 2” list following withdrawal of their nominations; removal from Category 2 does not by itself place a substance on the 503A Bulks List, and such substances remain outside compliant compounding until formally added. PCAC recommendations are advisory, and the committee’s outcome is not final until the FDA issues its own determination. This process concerns compounding-pharmacy permissions only; it does not change the status of thymosin beta-4 as a compound supplied strictly for laboratory research. Researchers remain responsible for compliance with all applicable regulations in their jurisdiction. (See the PYXAX peptide-compliance landscape guide for the full regulatory picture.)

Section 8 — PYXAX Verification Standard

Every PYXAX batch is independently third-party tested by accredited laboratories including ILS Labs, Krause Analytical, and Janoshik. Batch-specific COAs are published for every lot, naming the accredited lab that tested that batch.

Testing panel:

• Chromatographic purity by HPLC
• Molecular identity by LC-MS
• Endotoxin (USP <85> LAL method)
• Heavy metals by ICP-MS
• QR-verified, batch-specific COA published for every lot

Lot-specific documentation. Every production lot receives its own batch number. The batch number on the vial matches the batch number on the COA in the PYXAX COA Library, so researchers can confirm identity — including the exact sequence supplied — before ordering.

Community verification. Select lots are submitted to Janoshik Analytical for community verification, with results publicly searchable by batch number — no vendor contact required. Founding batches were verified through Krause Analytical (accredited US laboratory), and ongoing production lots are tested across the accredited-laboratory network described above, with a batch-specific COA published for every lot.

View PYXAX TB-500 (Thymosin Beta-4) →
View COA Library →
Read The PYXAX Standard →

Additional resources: pyxax.com/shop/ · pyxax.com/coa-library/ · pyxax.com/standard/

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.